Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy

Por Thakurta, A, Gandhi, A K, Waldman, M F, Bjorklund, C, Ning, Y, Mendy, D, Schafer, P, Lopez-Girona, A, Lentzsch, S, Schey, S A, Calle, Y, Chelliah, R, Orlowski, R Z, Madan, A, Avet-Loiseau, H, Chopra, R
Publicado em 2014

Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF...

Por Bjorklund, C C, Lu, L, Kang, J, Hagner, P R, Havens, C G, Amatangelo, M, Wang, M, Ren, Y, Couto, S, Breider, M, Ning, Y, Gandhi, A K, Daniel, T O, Chopra, R, Klippel, A, Thakurta, A G
Publicado no Blood Cancer J (2015)

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

Por Lopez-Girona, A, Mendy, D, Ito, T, Miller, K, Gandhi, A K, Kang, J, Karasawa, S, Carmel, G, Jackson, P, Abbasian, M, Mahmoudi, A, Cathers, B, Rychak, E, Gaidarova, S, Chen, R, Schafer, P H, Handa, H, Daniel, T O, Evans, J F, Chopra, R
Publicado em 2012

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

Por Lopez-Girona, A, Mendy, D, Ito, T, Miller, K, Gandhi, A K, Kang, J, Karasawa, S, Carmel, G, Jackson, P, Abbasian, M, Mahmoudi, A, Cathers, B, Rychak, E, Gaidarova, S, Chen, R, Schafer, P H, Handa, H, Daniel, T O, Evans, J F, Chopra, R
Publicado em 2012